Spatial control of the βAR system in heart failure: the transverse tubule and beyond.
The beta1-adrenoceptors (β(1)AR) and beta-2 (β(2)AR) adrenoceptors represent the predominant pathway for sympathetic control of myocardial function. Diverse mechanisms have evolved to translate signalling via these two molecules into differential effects on physiology. In this review, we discuss how the functions of the βAR are organized from the level of secondary messengers to the whole heart to achieve this. Using novel microscopy and bio-imaging methods researchers have uncovered subtle organization of the control of cyclic adenosine monophosphate (cAMP), the predominant positively inotropic pathway for the βAR. The β(2)AR in particular is demonstrated to give rise to highly compartmentalized, spatially confined cAMP signals. Organization of β(2)AR within the T-tubule and caveolae of cardiomyocytes concentrates this receptor with molecules which buffer and shape its cAMP signal to give fine control. This situation is undermined in various forms of heart failure. Human and animal models of heart failure demonstrate disruption of cellular micro-architecture which contributes to the change in response to cardiac βARs. Loss of cellular structure has proved key to the observed loss of confined β(2)AR signalling. Some pharmacological and genetic treatments have been successful in returning failing cells to a more structured phenotype. Within these cells it has been possible to observe the partial restoration of normal β(2)AR signalling. At the level of the organ, the expression of the two βAR subtypes varies between regions with the β(2)AR forming a greater proportion of the βAR population at the apex. This distribution may contribute to regional wall motion abnormalities in Takotsubo cardiomyopathy, a syndrome of high sympathetic activity, where the phosphorylated β(2)AR can signal via Gi protein to produce negatively inotropic effects.
Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College, 4th floor, Imperial Centre for Translational and Experimental Medicine, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. j.gorelik@ic.ac.uk
Julia
J
Gorelik
Peter T
PT
Wright
Alexander R
AR
Lyon
Sian E
SE
Harding
D027241:Amino Acid Transport System y+L / Q000502:physiology; D000818:Animals; D021941:Caveolae / Q000502:physiology; D000242:Cyclic AMP / Q000502:physiology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000502:physiology; D004195:Disease Models, Animal; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D009200:Myocardial Contraction; D032383:Myocytes, Cardiac / Q000502:physiology*; D009363:Neoplasm Proteins / Q000502:physiology; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D012519:Sarcoplasmic Reticulum / Q000502:physiology* / Q000648:ultrastructure; D015398:Signal Transduction / Q000502:physiology
D027241:Amino Acid Transport System y+L; D009363:Neoplasm Proteins; D011943:Receptors, Adrenergic, beta; C115131:SLC43A1 protein, human; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases